{"entity":{"type":"insider","cik":"0001669737","url":"/insider/0001669737","json_url":"/insider/0001669737.json","name":"Dahan Michel","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":25,"n_filings":19,"first":"2016-04-05","last":"2024-05-14","span_basis":"filed_date"},"name_variants":[{"name":"Dahan Michel","source":"filing","n_filings":19,"first_seen":"2016-04-05","last_seen":"2024-05-14"}],"transactions":[{"id":2632800,"accession":"0001562180-24-004025","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-24-004025","line_url":"/filing/0001562180-24-004025#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34840.0,"shares_display":"34,840","price_per_share":1.26,"price_display":"1.26","price_state":"stated","total_value":43898.4,"total_display":"43,898.40","total_whole":"43,898","shares_owned_after":672092.0,"shares_owned_after_display":"672,092","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-13","filed_date":"2024-05-14","scope":"insider"},{"id":3128976,"accession":"0001562180-24-002023","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-24-002023","line_url":"/filing/0001562180-24-002023#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8661.0,"shares_display":"8,661","price_per_share":1.58,"price_display":"1.58","price_state":"stated","total_value":13684.38,"total_display":"13,684.38","total_whole":"13,684","shares_owned_after":706932.0,"shares_owned_after_display":"706,932","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-29","filed_date":"2024-03-01","scope":"insider"},{"id":2401924,"accession":"0001562180-24-001994","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-24-001994","line_url":"/filing/0001562180-24-001994#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10744.0,"shares_display":"10,744","price_per_share":1.52,"price_display":"1.52","price_state":"stated","total_value":16330.88,"total_display":"16,330.88","total_whole":"16,331","shares_owned_after":715593.0,"shares_owned_after_display":"715,593","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-27","filed_date":"2024-02-29","scope":"insider"},{"id":7814095,"accession":"0001562180-23-004503","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-23-004503","line_url":"/filing/0001562180-23-004503#line-2","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":95478.0,"shares_display":"95,478","price_per_share":1.2229,"price_display":"1.22","price_state":"stated","total_value":116760.0462,"total_display":"116,760.05","total_whole":"116,760","shares_owned_after":574037.0,"shares_owned_after_display":"574,037","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-25","filed_date":"2023-05-25","scope":"insider"},{"id":7977733,"accession":"0001562180-23-002198","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001562180-23-002198","line_url":"/filing/0001562180-23-002198","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20412.0,"shares_display":"20,412","price_per_share":0.8775,"price_display":"0.88","price_state":"stated","total_value":17911.53,"total_display":"17,911.53","total_whole":"17,912","shares_owned_after":271393.0,"shares_owned_after_display":"271,393","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-01","filed_date":"2023-03-03","scope":"insider","n_lines":3},{"id":8235408,"accession":"0001562180-23-002039","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-23-002039","line_url":"/filing/0001562180-23-002039#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10090.0,"shares_display":"10,090","price_per_share":0.8132,"price_display":"0.81","price_state":"stated","total_value":8205.188,"total_display":"8,205.19","total_whole":"8,205","shares_owned_after":289927.0,"shares_owned_after_display":"289,927","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-27","filed_date":"2023-03-01","scope":"insider"},{"id":6862779,"accession":"0001562180-22-002163","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001562180-22-002163","line_url":"/filing/0001562180-22-002163","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14978.0,"shares_display":"14,978","price_per_share":2.1707,"price_display":"2.17","price_state":"stated","total_value":32512.7446,"total_display":"32,512.74","total_whole":"32,513","shares_owned_after":302122.0,"shares_owned_after_display":"302,122","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-01","filed_date":"2022-03-02","scope":"insider","n_lines":3},{"id":6862764,"accession":"0001562180-22-002163","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-22-002163","line_url":"/filing/0001562180-22-002163#line-2","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6555.0,"shares_display":"6,555","price_per_share":2.1548,"price_display":"2.15","price_state":"stated","total_value":14124.714,"total_display":"14,124.71","total_whole":"14,125","shares_owned_after":258995.0,"shares_owned_after_display":"258,995","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-28","filed_date":"2022-03-02","scope":"insider"},{"id":4940624,"accession":"0001562180-21-002541","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-21-002541","line_url":"/filing/0001562180-21-002541#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1211.0,"shares_display":"1,211","price_per_share":3.4,"price_display":"3.40","price_state":"stated","total_value":4117.4,"total_display":"4,117.40","total_whole":"4,117","shares_owned_after":265550.0,"shares_owned_after_display":"265,550","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-01","filed_date":"2021-04-01","scope":"insider"},{"id":4560456,"accession":"0001562180-21-001784","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001562180-21-001784","line_url":"/filing/0001562180-21-001784","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14547.0,"shares_display":"14,547","price_per_share":3.3961,"price_display":"3.40","price_state":"stated","total_value":49403.0667,"total_display":"49,403.07","total_whole":"49,403","shares_owned_after":255113.0,"shares_owned_after_display":"255,113","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-01","filed_date":"2021-03-02","scope":"insider","n_lines":2},{"id":2530520,"accession":"0001562180-20-001937","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-20-001937","line_url":"/filing/0001562180-20-001937#line-2","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6972.0,"shares_display":"6,972","price_per_share":8.7,"price_display":"8.70","price_state":"stated","total_value":60656.4,"total_display":"60,656.40","total_whole":"60,656","shares_owned_after":204960.0,"shares_owned_after_display":"204,960","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-28","filed_date":"2020-03-02","scope":"insider"},{"id":4755672,"accession":"0001562180-17-003205","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-17-003205","line_url":"/filing/0001562180-17-003205#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1398.0,"shares_display":"1,398","price_per_share":19.64,"price_display":"19.64","price_state":"stated","total_value":27456.72,"total_display":"27,456.72","total_whole":"27,457","shares_owned_after":95826.0,"shares_owned_after_display":"95,826","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-10-02","filed_date":"2017-10-04","scope":"insider"},{"id":4318485,"accession":"0001562180-17-003085","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-17-003085","line_url":"/filing/0001562180-17-003085#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":19.3,"price_display":"19.30","price_state":"stated","total_value":96500.0,"total_display":"96,500.00","total_whole":"96,500","shares_owned_after":97224.0,"shares_owned_after_display":"97,224","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-28","filed_date":"2017-10-02","scope":"insider"},{"id":4155885,"accession":"0001562180-17-002729","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-17-002729","line_url":"/filing/0001562180-17-002729#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":75000.0,"total_display":"75,000.00","total_whole":"75,000","shares_owned_after":102224.0,"shares_owned_after_display":"102,224","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-08-15","filed_date":"2017-08-17","scope":"insider"},{"id":4201392,"accession":"0001562180-17-002435","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-17-002435","line_url":"/filing/0001562180-17-002435#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1399.0,"shares_display":"1,399","price_per_share":14.2577,"price_display":"14.26","price_state":"stated","total_value":19946.5223,"total_display":"19,946.52","total_whole":"19,947","shares_owned_after":107224.0,"shares_owned_after_display":"107,224","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-03","filed_date":"2017-07-06","scope":"insider"},{"id":4466670,"accession":"0001562180-17-001431","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-17-001431","line_url":"/filing/0001562180-17-001431#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1401.0,"shares_display":"1,401","price_per_share":9.1775,"price_display":"9.18","price_state":"stated","total_value":12857.6775,"total_display":"12,857.68","total_whole":"12,858","shares_owned_after":108623.0,"shares_owned_after_display":"108,623","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-04-03","filed_date":"2017-04-04","scope":"insider"},{"id":4679999,"accession":"0001562180-17-000082","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-17-000082","line_url":"/filing/0001562180-17-000082#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1629.0,"shares_display":"1,629","price_per_share":10.4906,"price_display":"10.49","price_state":"stated","total_value":17089.1874,"total_display":"17,089.19","total_whole":"17,089","shares_owned_after":70524.0,"shares_owned_after_display":"70,524","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-01-01","filed_date":"2017-01-03","scope":"insider"},{"id":3178619,"accession":"0001562180-16-003207","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-16-003207","line_url":"/filing/0001562180-16-003207#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1401.0,"shares_display":"1,401","price_per_share":8.9548,"price_display":"8.95","price_state":"stated","total_value":12545.6748,"total_display":"12,545.67","total_whole":"12,546","shares_owned_after":72153.0,"shares_owned_after_display":"72,153","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-10-01","filed_date":"2016-10-04","scope":"insider"},{"id":2138010,"accession":"0001562180-16-002778","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-16-002778","line_url":"/filing/0001562180-16-002778#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1402.0,"shares_display":"1,402","price_per_share":7.4665,"price_display":"7.47","price_state":"stated","total_value":10468.033,"total_display":"10,468.03","total_whole":"10,468","shares_owned_after":73554.0,"shares_owned_after_display":"73,554","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-05","filed_date":"2016-07-06","scope":"insider"},{"id":3172513,"accession":"0001209191-16-112919","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-112919","line_url":"/filing/0001209191-16-112919#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001669737","owner_name":"Dahan Michel","owner_display_name":"Dahan Michel","owner_url":"/insider/0001669737","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1401.0,"shares_display":"1,401","price_per_share":9.41,"price_display":"9.41","price_state":"stated","total_value":13183.41,"total_display":"13,183.41","total_whole":"13,183","shares_owned_after":74956.0,"shares_owned_after_display":"74,956","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-04-04","filed_date":"2016-04-05","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":25,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":25,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":25},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001517022","name":"Akebia Therapeutics, Inc.","url":"/issuer/0001517022","role":"Officer (SVP, Chief Operating Officer)","n_filings":19,"first_seen":"2016-04-05","last_seen":"2024-05-14"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001669737","retrieved_at":"2026-08-23T14:27:05+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}